VEGFA and neoplasm: The most recent open-label, single center, single-arm, phase 3 study indicates clinical effectiveness of another multikinase inhibitor, lanvatinib, in the therapy of unresectable mCRC patients, especially refractory or intolerant to classical chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (tumor with wt-RAS expression) [163].